A Phase 1/2 interventional study of Crovalimab and Placebo in Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Hoffmann-La Roche. Completed at 15 sites in 7 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hemoglobinuria, Paroxysmal with a site in Japan — 1 open to participants now, 5 under way, 5 of them phase 3. Hemoglobinuria, Paroxysmal · Japan.
Among the 14 studies in Hemoglobinuria, Paroxysmal with a site in Japan, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is the only one in phase 1/2, and was the 3rd registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →1 of the 14 studies in Hemoglobinuria, Paroxysmal with a site in Japan is open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Japan, Brazil, Canada and 18 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 11
First in 2015; this study’s year is marked. 2 started in 2016.
This study's enrollment of 59 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 190 across the 13 interventional studies, 132 across the 1 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 5 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
2 of the studies in Hemoglobinuria, Paroxysmal with a site in Japan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Hemoglobinuria, Paroxysmal with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of crovalimab will be evaluated in participants with paroxysmal nocturnal hemoglobinuria (PNH) in parts 2, 3, 4, and OLE of the study. Efficacy of crovalimab will be evaluated in Parts 2, 3, and 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1 (HVs only):
Parts 2, 3 and 4 (PNH participants only):
Part 2 and 4 (currently untreated PNH participants who are candidates for treatment with complement inhibitors only):
Part 3 and 4 (PNH participants currently treated with eculizumab only):
OLE only - PNH participants:
All Parts:
Exclusion Criteria:
Part 1 (HVs only):
Parts 2, 3 and 4 - PNH participants only:
Part 3 and 4 - PNH patients only:
All Parts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg) intravenous (IV) infusion. Doses are planned to be escalated up to Cohort 5.
Drug: Crovalimab
Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
Drug: Placebo
PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg IV of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
Drug: Crovalimab
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg weekly (QW) starting on Day 8 for a maximum treatment duration of 5 months.
Drug: Crovalimab
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg every 2 weeks (Q2W) for a maximum treatment duration of 5 months.
Drug: Crovalimab
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg every 4 weeks (Q4W) starting on Day 8 for a maximum treatment duration of 5 months.
Drug: Crovalimab
PNH Participants pretreated with eculizumab will receive crovalimab: Participants \>/= 100 kilograms (kg): loading dose of 1500 mg IV on Day 1; Participants \< 100 kg: loading dose of 1000 mg IV on Day 1. In all Participants, the remainder of the loading series schedule will be 340 mg subcutaneous (SC) on Days 2, 8, 15, and 22. For Participants \>/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients \< 100 kg will receive a maintenance dose of 680 mg SC on the same schedule.
Drug: Crovalimab
Treatment naïve PNH Participants will receive: Participants \>/= 100 kg: loading dose of 1500 mg IV on day 1; Participants \< 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants \>/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients \< 100 kg will receive a maintenance dose of 680 mg SC on the same schedule.
Drug: Crovalimab
PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight \>/= 40 kg to \< 100 kg) or 1020 mg SC Q4W (body weight \>/= 100 kg) for up to a maximum treatment duration of ten years from entry into OLE.
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm.
Placebo will be administered as per schedule described in Part 1 placebo arm.
Part 1: Percentage of Participants With Dose-Limiting Events (DLEs)
Time frame: Baseline up to approximately 3 months
Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to approximately 3 months
Part 2: Percentage of Participants With AEs and SAEs
Time frame: Baseline up to approximately 8 months
Part 3: Percentage of Participants With AEs and SAEs
Time frame: Baseline up to approximately 8 months
Part 4: Percentage of Participants With AEs and SAEs
Time frame: Baseline up to approximately 8 months
Part 2: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)
Time frame: Baseline up to Day 224
Part 3: Terminal Complement Activity as Assessed by Ex Vivo Liposome Lysis in Serum Using the LIA
Time frame: Baseline up to Day 224
Part 4: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)
Time frame: Baseline up to Day 224
OLE: Percentage of Participants With AEs and SAEs
Time frame: OLE: Week 21 up to Week 567
Part 1: Terminal Complement Activity as Assessed by Ex Vivo Liposome Immunoassay (LIA)
Time frame: Part 1: Baseline up to Day 91 (assessed at predose [Hour 0], end of infusion [EOI] [1 Hour], Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91)
Part 2: Serum Lactate Dehydrogenase (LDH) Levels
Time frame: Predose (Hour 0), Hours 10-12 on Days 1, 8; Days 2, 5, 9, 15, 22, 29, 36, 43, 50, 64, 78, 92, 106, 120, 134, 224
Part 3: Serum LDH Levels
Time frame: Part 3: Predose (Hour 0), Hours 10-12 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 64, 78, 92, 106, 134; Day 224
Part 4: Serum LDH Levels
Time frame: Part 4: Predose (Hour 0), Hour 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 43, 57, 85, 113, 134; Day 224
Part 1: Total Complement Component 5 (C5) Concentration
Time frame: Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91
Part 2: Total C5 Concentration
Time frame: Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Days 36, 43, 50, 64, 78, 92, 106, 120, 134
Part 3: Total C5 Concentration
Time frame: Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2 and 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224
Part 4: Total C5 Concentration
Time frame: Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224
Part 1: Free C5 Concentration
Time frame: Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91
Part 2: Free C5 Concentration
Time frame: Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Day 36, 43, 50, 64, 78, 92, 106, 120, 134
Part 3: Free C5 Concentration
Time frame: Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224
Part 4: Free C5 Concentration
Time frame: Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224
Part 2: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score at Day 64
Time frame: Baseline, Day 64
Part 3: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 50, 78, 106, and 134
Time frame: Baseline, Day 8, 22, 50, 78, 106, 134
Part 4: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 57, 85, 113 and 134
Time frame: Baseline, Day 8, 22, 57, 85, 113, 134
Part 2: Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 64
Time frame: Baseline, Day 64
Part 3: Change From Baseline in HRQoL as Measured by EORTC QLQ-C30 Score at Day 78 and 134
Time frame: Baseline, Day 78, 134
Part 4: Change From Baseline in HRQoL as Measured by EORTC QLQC30 Score at Day 85 and 134
Time frame: Baseline, Day 85, 134
Part 2: Participant Treatment Satisfaction as Measured by Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Day 8, 22, 36, 50 and 64
Time frame: Baseline, Day 8, 22, 36, 50, 64
Part 3: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 50
Time frame: Baseline, Day 8, 50
Part 4: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 57
Time frame: Baseline, Day 8, 57
Part 2: Number of Packed Red Blood Cell (RBC) Units Transfused per Participant
Time frame: Baseline up to Day 224
Part 3: Number of Packed RBCs Units Transfused per Participant
Time frame: Baseline up to Day 224
Part 4: Number of Packed RBCs Units Transfused per Participant
Time frame: Baseline up to Day 224
Part 2: Percentage of Participants With Packed RBC Units Transfused
Time frame: Baseline up to Day 224
Part 3: Percentage of Participants With Packed RBC Units Transfused
Time frame: Baseline up to Day 224
Part 4: Percentage of Participants With Packed RBC Units Transfused
Time frame: Baseline up to Day 224
Part 1: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab
Time frame: Part 1: Day 1 up to Day 91 (assessed at predose [Hour 0] on Day 1; on Days 14, 28, 56, 84, and 91)
Part 2: Percentage of Participants With ADAs to Crovalimab
Time frame: Part 2: Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 50, 106, 134); Days 29, 224
Part 3: Percentage of Participants With ADAs to Crovalimab
Time frame: Part 3: Day 1 up to Day 106 assessed at predose [Hour 0] on Days 1, 8, 29, 64, and 106; Day 224
Part 4: Percentage of Participants With ADAs to Crovalimab
Time frame: Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 29, 113); Days 134, 224
OLE: Total C5 Concentration
Time frame: OLE: Predose (Hour 0) on Week 36 up to Week 521
OLE: Serum LDH Levels
Time frame: OLE: Predose (Hour 0) on Week 28 up to Week 521
OLE: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)
Time frame: OLE: Week 36 up to Week 521
Part 2: Percentage of Participants With LDH Below Upper Limit of Normal (ULN)
Time frame: Baseline up to Day 224
Part 3: Percentage of Participants With LDH Below ULN
Time frame: Baseline up to Day 224
Part 4: Percentage of Participants With LDH Below ULN
Time frame: Baseline up to Day 224
Part 2: Percentage of Participants With Complement Suppression
Time frame: Baseline up to Day 134
Part 3: Percentage of Participants With Complement Suppression
Time frame: Baseline up to Day 134
Part 4: Percentage of Participants With Complement Suppression
Time frame: Baseline up to Day 134
Part 2: Monthly Rate of pRBC Transfusions per Participant
Time frame: Baseline up to 10 years
Part 3: Monthly Rate of pRBC Transfusions per Participant
Time frame: Baseline up to 10 years
Part 4: Monthly Rate of pRBC Transfusions per Participant
Time frame: Baseline up to 10 years
Part 2: Proportion of Transfusion-Free Participants
Time frame: Baseline up to 10 years
Part 3: Proportion of Transfusion-Free Participants
Time frame: Baseline up to 10 years
Part 4: Proportion of Transfusion-Free Participants
Time frame: Baseline up to 10 years
Part 2: Annual Rate of Transfusion Avoidance per Participant
Time frame: Baseline up to 10 years
Part 3: Annual Rate of Transfusion Avoidance per Participant
Time frame: Baseline up to 10 years
Part 4: Annual Rate of Transfusion Avoidance per Participant
Time frame: Baseline up to 10 years
Part 2: Annual Rate of Breakthrough Hemolysis (BTH)
Time frame: Baseline up to 10 years
Part 3: Annual Rate of Breakthrough Hemolysis (BTH)
Time frame: Baseline up to 10 years
Part 4: Annual Rate of Breakthrough Hemolysis (BTH)
Time frame: Baseline up to 10 years
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical -trials/data-sharing/)
Ran from Nov 2016 to primary completion in Aug 2026, 116 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crovalimab